Increasing awareness within the U.S. capital markets
DiagnaMed focused on commercializing CERVAI™, its proprietary Brain Health AI Platform leveraging Generative AI
TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health AI company, is pleased to announce that it has applied for uplisting of its common shares to be trading on the OTCQB® Venture Market (“OTCQB”). The Company will continue to trade on the Canadian Securities Exchange (“CSE”) under its existing symbol "DMED”.
"We are pleased to have initiated the process to list our common shares on the OTCQB as part of our strategy on providing additional liquidity and building our awareness to a broader range of institutional and retail investors in the U.S. as we near the commercialization of CERVAI™, our proprietary Brain Health AI Platform leveraging Generative AI, for mental health and neurological disorders,” said Fabio Chianelli, Chairman of DiagnaMed.
The Company has already submitted its Form 211 to the Financial Industry Regulatory Authority (“FINRA”) which, if accepted, will qualify the Company’s shares to trade in the U.S. on the OTC market. The Company will also apply to the Depository Trust Company (“DTC”) for DTC eligibility which would greatly simplify the process of trading the Company’s common shares. The listing of the Company's common shares on the OTCQB remains subject to the approval of the OTCQB and the satisfaction of applicable listing requirements. As more information becomes available, the Company will keep its shareholders up to date on the status of the application.
The OTCQB, operated by OTC Markets Group Inc., is the premiere marketplace for early stage and developing U.S. and international companies that are committed to providing a high-quality trading and information experience for their U.S. investors. Companies must be current in their financial reporting to undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. The OTCQB quality standards provide a strong baseline of transparency as well as the technology and regulation to improve the information and trading experience for investors. The OTCQB is recognized by the Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. Investors can find real-time quote and market information for the Company, once listed, at https://www.otcmarkets.com.
About CERVAI™
CERVAI™ is a brain health AI platform leveraging generative AI that aims to predict and monitor brain age and provide actionable insights and tools to diagnose, prevent or improve cognitive decline for mental health and neurodegenerative disorders. CERVAI™ consists of an electroencephalogram-based (“EEG”) headset and machine-learning technique and integrates proprietary software and web applications into a unified turnkey pipeline of standardized EEG and data recording protocols and unique brain health assessment tools generated rapidly by self-report or clinician-observed measures, each capturing different aspects of brain health to evaluate overall brain health, output a patient risk score, and provide actionable points generated by GPT-3 to develop precision medicine-like, personalized treatment plans and interventions for mental health and neurodegenerative conditions.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED), a digital health AI company, is focused on the development and commercialization of CERVAI™, a proprietary Brain Health AI Platform leveraging Generative AI, for mental health and neurodegenerative disorders. Learn more at DiagnaMed.com.
For more information about DiagnaMed, please contact:
Fabio Chianelli
Chairman of the Board
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in DiagnaMed's final prospectus dated October 26, 2022, which is available on the Company's profile at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
